IP Verse

Dosage Regimen For A S1P Receptor Agonist - EP3409274B1

PatentPatent Analysis

EP3409274

NOVARTIS
Application Number
EP18179301A
Filing Date
Dec 21, 2009
Status
Revoked
Dec 6, 2024
Grant Date
Nov 20, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Bibliography

The patent EP3409274B1 was granted to Novartis on Nov 20, 2019 following the initial filing on Dec 21, 2009 under the application number EP18179301A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HAMM & WITTKOPPAug 18, 2020WITHDRAWN
VON SEEBACHAug 18, 2020WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents